VJVirtual | Reactivating antitumor efficacy of anti-PD-1 therapy with MRx0518

Alex Stevenson, PhD, 4D Pharma plc, Leeds, UK, discusses an ongoing trial (NCT03637803) of MRx0518 in combination with pembrolizumab, an anti-PD-1 checkpoint inhibitor, in patients with secondary resistance to pembrolizumab. MRx0518 is a single-strain live biotherapeutic product with anti-tumorigenic efficacy. Promising interim results demonstrate the immunostimulatory benefits of MRx0518 as a monotherapy but also in reactivation of previous checkpoint blockade therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).